• Gene Editing Center (GEC) seeks to perform innovative research and develop new technologies with intellectual property rights and translational potentials. GEC also builds up an international team of research and professionals familiar to the policies and regulations of the biomedical industry. According to national strategicplan in gene editing field, GEC will focus on development of gene editing tools, delivery and preparation of gene editing vectors, gene editing therapy, rapid detection of virus and CRISPR mechanism. In the future, GEC aims to become a comprehensive and international innovation center in the gene editing field.



  • Development of high precision editing tool
  • High-efficiency and high-accuracy single base editing system
  • Optimization of gene modification system with improved efficiency


  • Gene editing therapy
  • Gene editing therapy for thalassemia
  • Gene editing therapy for juvenile macular malnutrition


  • Preparation and delivery of gene editing vector
  • Delivery of novel gene modification tools by non-viral vectors
  • Exploring chemical modification of new gene modification tools


  • Rapid detection of virus
  • Design and synthesis of crRNA library
  • Screening of suitable Cas13 homologs and optimization
  • Optimization of nucleic acid amplification system
  • Optimization of crRNA
  • Optimization of nucleic acid cleavage system


  • Exploration, improvement and application of CRISPR system
  • Exploration of CRISPR activity and mechanism
  • Engineering of Cas protein
  • Application of molecular mechanism
  • Drug target screening



  • 03
    The prime editing (PE) system can install small insertions and deletions in addition to various base substitutions. Two recent studies published in Nature Biotechnology by Choi et al. and Jiang et al. report that the system can also be tweaked for efficient and precise deletions of large DNA fragments.
  • 01
    Cancer cells acquire genetic heterogeneity to escape from immune surveillance during tumor evolution, but a systematic approach to distinguish driver from passenger mutations is lacking. Here we investigate the impact of different immune pressure on tumor clonal dynamics and immune evasion mechanism, by combining massive parallel sequencing of immune edited tumors and CRISPR library screens in syngeneic mouse tumor model and co-culture system. We find that the core microRNA (miRNA) biogenesis an
  • 25
    Streptococcus pyogenes Cas9 (SpCas9), a programmable RNA-guided DNA endonuclease, has been widely repurposed for biological and medical applications. Critical interactions between SpCas9 and DNA confer the high specificity of the enzyme in genome engineering. Here, we unveil that an essential SpCas9–DNA interaction located beyond the protospacer adjacent motif (PAM) is realized through electrostatic forces between four positively charged lysines among SpCas9 residues 1151–1156 and the negatively
  • 22
    Rhinoviruses (RVs) cause more than half of common colds and, in some cases, more severe diseases. Functional genomics analyses of RVs using siRNA or genome-wide CRISPR screen uncovered a limited set of host factors, few of which have proven clinical relevance.Herein, we systematically compare genome-wide CRISPR screen and surface protein-focused CRISPR screen, referred to as surfaceome CRISPR screen, for their efficiencies in identifying RV host factors. We find that surfaceome screen outperform
  • 15
    DNA base editors, comprising nucleotide deaminases and catalytically impaired Cas9 nickase, have been widely used in various organisms for the efficient creation of point mutations, providing researchers with powerful tools in precise genome editing. However, they have been limited by the scope of the editing. The discovery and engineering of various CRISPR-Cas systems, especially SpCas9 variants xCas9, Cas9-NG, and Cas9-SpRY, have diversified the range of targetable DNA sequences and expanded t
  • 10
    The fusion of CRISPR–Cas9 with cytidine deaminases leads to base editors (BEs) capable of programmable C-to-T editing, which has potential in clinical applications but suffers from off-target (OT) mutations. Here, we used a cleavable deoxycytidine deaminase inhibitor (dCDI) domain to construct a transformer BE (tBE) system that induces efficient editing with only background levels of genome-wide and transcriptome-wide OT mutations. After being produced, the tBE remains inactive at OT sites with